Reaction

Symptom Recurrence reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 5,790 reports · 116 co-occurring drugs

As of the last recalculation, Symptom Recurrence appears in 5,790 FAERS reports alongside 116 co-occurring drug terms. The strongest observed disproportionality signal is NIRMATRELVIR AND RITONAVIR (PRR 79.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Nirmatrelvir And Ritonavir	994	79.5	81.0
Ravulizumab	243	67.4	68.7
Avapritinib	74	22.2	22.4
Rifaximin	108	18.9	19.0
Benralizumab	81	14.7	14.8
Canakinumab	41	13.7	13.8
Infliximab-Dyyb	81	10.1	10.1
Eculizumab	140	9.5	9.5
Naltrexone Hydrochloride And Bupropion Hydrochloride	22	9.3	9.3
Secukinumab	383	9.1	9.1
Mepolizumab	120	8.8	8.9
Asfotase Alfa	24	8.6	8.7
Cetirizine Hydrochloride Allergy	65	7.8	7.8
Cetirizine Hydrochloride Tablets	65	7.8	7.8
Mometasone	39	7.7	7.7
Omalizumab	177	7.7	7.7
Belimumab	62	7.1	7.1
Lanreotide Acetate	14	6.4	6.4
Estradiol Gel 0.1%	78	6.3	6.3
Estradiol Transdermal	78	6.3	6.3
Ciclesonide	22	5.8	5.8
Aripiprazole Oral	66	5.8	5.8
Aripiprazole Orally Disintegrating	66	5.8	5.8
Cefuroxime	17	5.4	5.4
Tofacitinib Citrate	19	5.2	5.2
Brexpiprazole	24	5.2	5.2
Anakinra	23	5.0	5.0
Estradiol	115	4.9	4.9
Cetirizine	101	4.7	4.7
Methimazole	10	4.6	4.6
Acetylcysteine	12	4.6	4.6
Adalimumab-Aaty	57	4.4	4.4
Adalimumab-Adaz	63	4.3	4.3
Pancrelipase	44	4.1	4.1
Cortisone Acetate	14	4.1	4.1
Ofatumumab	37	4.0	4.0
Aripiprazole	131	3.9	3.9
Dupilumab	487	3.9	3.9
Fluticasone Furoate	13	3.9	3.9
Pseudoephedrine Hydrochloride	11	3.9	3.9
Cetiirizine	45	3.8	3.8
Zinc	26	3.8	3.8
Zinc Chloride	26	3.8	3.8
Adalimumab-Fkjp	48	3.7	3.8
Thyroid, Porcine	11	3.7	3.7
Budesonide	59	3.6	3.6
Pseudoephedrine Hcl	11	3.6	3.6
Zinc Gluconate	26	3.6	3.6
Human Immunoglobulin G	20	3.5	3.5
Montelukast Sodium	116	3.5	3.5
Montelukast	80	3.5	3.5
Diphenhydramine	58	3.3	3.3
Hydroxyzine Hydrochloride	12	3.3	3.3
Hydroxyzine Hydrochloride Oral	12	3.3	3.3
Doxepin	9	3.2	3.2
Progesterone	20	3.2	3.2
Cetirizine Hydrochloride	142	3.1	3.2
Doxepin Hydrochloride	11	3.1	3.1
Diphenhydramine Hydrochloride	132	2.9	2.9
Bimekizumab	17	2.9	2.9
Desoximetasone	15	2.8	2.8
Umeclidinium	7	2.8	2.8
Clobetasol Propionate Ointment Usp, 0.05%	8	2.8	2.8
Clobetasol Propionate	8	2.8	2.8
Bupropion Hydrochloride	75	2.8	2.8
Colchicine	20	2.7	2.7
Fluticasone Propionate Nasal	23	2.7	2.7
Alendronate Sodium Tablet	14	2.7	2.7
Vigabatrin	11	2.7	2.7
Vibegron	6	2.7	2.7
Mesalamine	41	2.6	2.6
Fluticasone Furoate And Vilanterol Trifenatate	26	2.6	2.6
Budesonide And Formoterol Fumarate Dihydrate	69	2.6	2.6
Quetiapine Fumarate	21	2.6	2.6
Bupropion	30	2.4	2.4
Hydroxychloroquine	48	2.3	2.3
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	26	2.3	2.3
Oxazepam	13	2.2	2.2
Fexofenadine Hydrochloride	13	2.2	2.2
Diclofenac Potassium, Film Coated	5	2.1	2.1
Diclofenac Potassium Tablets	5	2.1	2.1
Risankizumab-Rzaa	48	2.1	2.1
Pitavastatin Calcium	6	2.1	2.1
Budesonide, Glycopyrrolate, And Formoterol Fumarate	6	2.1	2.1
Sarilumab	15	2.0	2.0
Loratadine Tablet	29	1.9	1.9
Tiotropium Bromide Inhalation Spray	6	1.9	1.9
Ziprasidone	9	1.8	1.8
Botulinum Toxin Type A	6	1.7	1.7
Umeclidinium Bromide And Vilanterol Trifenatate	8	1.7	1.7
Rimegepant Sulfate	6	1.7	1.7
Ustekinumab	48	1.7	1.7
Vortioxetine	8	1.7	1.7
Diclofenac Potassium	5	1.7	1.7
Selinexor	4	1.7	1.7
Upadacitinib	37	1.6	1.6
Linaclotide	12	1.6	1.6
Bosutinib	4	1.6	1.6
Agalsidase Beta	4	1.6	1.6
Guselkumab	14	1.4	1.4
Paliperidone	9	1.4	1.4
Oral Semaglutide	27	1.3	1.3
Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride And Dextrose	3	1.3	1.3
Ixekizumab	13	1.3	1.3
Fremanezumab-Vfrm	4	1.3	1.3
Alpelisib	3	1.2	1.2
Paliperidone Palmitate	11	1.2	1.2
Acalabrutinib	4	1.2	1.2
Eptinezumab-Jjmr	3	1.2	1.2
Apremilast	44	1.1	1.1
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	8	0.9	0.9
Droxidopa	5	0.8	0.8
Pimavanserin Tartrate	12	0.8	0.8
Tapentadol Hydrochloride	7	0.8	0.8
Galcanezumab-Gnlm	6	0.7	0.7
Erenumab-Aooe	8	0.5	0.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.